Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

Modlin IM(2006)Therapeutic options for gastrointestinal carcinoids Clin Gastroenterol Hepatol 4 526-547

Latich I(2009)Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues J Nucl Med 50 936-941

Kidd M(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656-4663

Zikusoka M(2002)Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 133-140

Eick G(2000)Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 273-282

Waser B(2009)High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience Cancer Biother Radiopharm 24 527-533

Tamma ML(2005)Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs J Nucl Med 46 S62-S66

Cescato R(2010)Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann Oncol 21 787-794

Maecke HR(2008)Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124-2130

Reubi JC(2005)Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets J Nucl Med 46 S187-S190

Modlin IM(2006)Therapeutic options for gastrointestinal carcinoids Clin Gastroenterol Hepatol 4 526-547

Latich I(2009)Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues J Nucl Med 50 936-941

Kidd M(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656-4663

Zikusoka M(2002)Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 133-140

Eick G(2000)Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 273-282

Waser B(2009)High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience Cancer Biother Radiopharm 24 527-533

Tamma ML(2005)Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs J Nucl Med 46 S62-S66

Cescato R(2010)Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann Oncol 21 787-794

Maecke HR(2008)Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124-2130

Reubi JC(2005)Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets J Nucl Med 46 S187-S190